Skip to main navigation Skip to search Skip to main content

Decreased Chronic GvHD With Post-Transplant Cyclophosphamide Versus ATG in Patients With Myelofibrosis Allografted With an Unrelated Donor: A Study From the Chronic Malignancies Working Party of the EBMT

  • Yves Chalandon*
  • , Edouard F. Bonneville
  • , Diderik-jan Eikema
  • , Liesbeth C. De Wreede
  • , Linda Koster
  • , Joe Tuffnell
  • , Jakob Passweg
  • , Johannes Schetelig
  • , Uwe Platzbecker
  • , Ibrahim Yakoub-Agha
  • , Urpu Salmenniemi
  • , Mareike Verbeek
  • , Moniek A. De Witte
  • , Jean-baptiste Mear
  • , John A. Snowden
  • , Tobias A. W. Holderried
  • , Gwendolyn Van Gorkom
  • , Frederic Baron
  • , Marie Robin
  • , Xavier Poire
  • Mieke W. H. Roeven, Maija Itala-remes, Jan Zaucha, Kavita Raj, Joanna Drozd-sokolowska, Giorgia Battipaglia, Tomasz Czerw, Juan Carlos Hernandez-boluda, Nicola Polverelli*, Donal P. Mclornan
*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Original languageEnglish
Pages (from-to)1308-1313
Number of pages6
JournalAmerican Journal of Hematology
Volume101
Issue number6
DOIs
Publication statusPublished - Jun 2026

Keywords

  • allogeneic hematopoietic stem cell transplantation
  • ATG
  • myelofibrosis
  • post-transplant cyclophosphamide
  • unrelated donor
  • TRANSPLANTATION
  • PREVENTION

Cite this